Wockhardt is currently trading at Rs. 1,685.00, up by 13.05 points or 0.78% from its previous closing of Rs. 1671.95 on the BSE.
The scrip opened at Rs. 1675.00 and has touched a high and low of Rs. 1685.90 and Rs. 1650.05 respectively. So far 1912 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 5 has touched a 52 week high of Rs. 1827.00 on 16-Nov-2012 and a 52 week low of Rs. 271.50 on 09-Jan-2012.
Last one week high and low of the scrip stood at Rs. 1700.00 and Rs. 1543.05 respectively. The current market cap of the company is Rs. 18186.65 crore.
The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 10.42% and 15.76% respectively.
Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy. Lamotrigine is the generic name for the brand Lamictal XR, marketed in the United States by Glaxo SmithKIine. Wockhardt is launching the product immediately and will be amongst the earliest generic versions of this product in the market.
According to IMS Health, the total market for this product in the US is about $250 million. Lamotrigine is used extensively in management of epilepsy. Wockhardt already markets several other products in the United States in the CNS segment, especially anti-convulsant drugs.
In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products has reaped the advantage of being an early entrant.
Wockhardt will be manufacturing the extended-release tablets of Lamotridine at its facility in Aurangabad, India. The technology for the extended release tablets were developed in-house.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |